Board of Directors
Mr. Cohen is an Advisor to Xeraya Capital. He has more 30 years of management, marketing and business development experience in life sciences and high technology companies. Mr. Cohen was the founding President and CEO of three early-stage biotechnology companies: Acacia Biosciences (acquired by Rosetta Inpharmatics), Cellerant Therapeutics and VitaPath Genetics. He served as CFO at GeneSoft Pharmaceuticals and has also held senior positions in business development and marketing at SEQUUS Pharmaceuticals and in the International, Management Services, and Information Technology business units at Baxter International. Mr. Cohen was the President and COO of ViTel International Inc., a pre-internet electronic messaging company. He also served as a management consultant with Monitor Company, working in the healthcare and high technology sectors. He was a member of the founding team of the Tufts Veterinary School and a regional manager of the National Health Professions Placement Network. Mr. Cohen is currently serving as CEO of Prime Biologics, a Xeraya portfolio company. He represents Xeraya on the boards of Chrono Therapeutics and Rapid Micro Biosystems. He holds a BA and an MA from Tufts University, and an MBA with distinction from Harvard Business School.
Senior Advisor and Co-Founder
Mr. Dornbush co-founded and served as Iconic’s Chief Executive Officer from 2007 until 2014. Prior to Iconic’s inception in 2003, Mr. Dornbush was President of Diem Investments, a private investment advisory firm. He continues to serve as Manager of Diem Bioventures, LLC, an investor in Iconic. Mr. Dornbush has served on numerous for profit and non-profit Boards including the Board of Directors of the National Park Foundation where he chaired the Foundation’s Investment Committee. Mr. Dornbush received a B.A. in English from The Colorado College and a J.D. from Boston University School of Law.
Mr. Foley has served as a member of Iconic Therapeutics’ Board of Directors since April 2014. He is a Managing Director with MPM Capital, a venture capital firm. Prior to joining MPM Capital in 1999, Mr. Foley worked in business development at Genentech and in management consulting with Arthur D. Little. He currently serves as a member of the Board of Directors of Rhythm, Chiasma, OSS, Selexys Pharmaceuticals and Valeritas. Mr. Foley received a B.S. in chemistry from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
William L. Greene, MD
Chief Executive Officer
Dr. Greene has served as Chief Executive Officer and a Director of Iconic Therapeutics since 2014. Dr. Greene joined Iconic from MPM Capital LLC, where he served as Managing Director and a member of the firm’s Investment Committee, leading investments and serving on Boards of Directors of emerging biopharmaceutical and medical device companies. His experience included Alnara (acquired by Eli Lilly:LLY), Alsius (Acquired, Zoll), Barrier Therapeutics (BTRX), Cotherix (CTRX), Idun Pharmaceuticals (acquired by Pfizer:PFE), and Intercell AG (ICLL, Vienna Stock Exchange).
Previously, Dr. Greene was a Senior Clinical Scientist and Epidemiologist at Genentech, Inc., with responsibility for clinical strategy, trial design and execution, and regulatory interactions in several therapeutic areas at all stages of development. While at Genentech, Dr. Greene led the early clinical development of Lucentis® among other products. Prior to Genentech, Dr. Greene was at Yale Medical School where he was a Resident in Internal Medicine and Diagnostic Radiology. He has been an Assistant Clinical Professor of Medicine at UCSF, active on the teaching staff of San Francisco General Hospital.
Dr. Greene is a co-founder of and Senior Advisor to Pear Therapeutics. His passion for using biotechnology to address significant unmet human needs extends to global health. He is an advisor to the Bill and Melinda Gates Foundation and is Chairman of the Investment Committee and on the Board of Directors of the Global Health Investment Fund, a pioneering initiative supported by the Foundation that brings together investors, philanthropists and industry to forge creative solutions to bring the fruits of biotechnology to the underserved around the world.
Dr. Greene received a B.A. degree from Wesleyan University and an M.D. degree from UCSF. Dr. Greene is a member of the American College of Physicians, was a Robert Wood Johnson Clinical Scholar at Yale in clinical epidemiology and a Howard Hughes Medical Institute Research Scholar at the NIH in neurobiology.
Julia P. Gregory
Ms. Gregory has served as a member of Iconic Therapeutics’ Board of Directors since April 2017. She is a seasoned biotechnology executive with CEO, CFO, board and investment banking skills. She has a proven track record of successfully growing, capitalizing and repositioning private and public biotechnology companies. She is well-versed in corporate governance and SEC issues. She has extensive experience in recruiting outstanding management teams and overcoming significant challenges. As a biotechnology executive, she has raised more than $1.5 billion for biotechnology companies across all types of business cycles and structured creative strategic alliances and transactions for them with pharmaceutical companies including GlaxoSmithKline, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company, Ltd., Genentech, Inc. (now Roche) and Human Genome Sciences (now GSK). Most recently, she was CEO and Board member of ContraFect, which focused on new biologics as an alternative to antibiotics. Prior to ContraFect, she was CEO and Board member of FivePrime Therapeutics, where she led a clinical-stage, biotechnology company discovering and developing innovative protein and antibody therapeutics in the fields of oncology and immunology. She was EVP Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. Prior to her corporate experience, Ms. Gregory was an investment banker for over 20 years primarily as Head of Healthcare and Investment Banking at Punk, Ziegel & Company and at Dillon, Read & Co, Inc. She received a B.A. in international affairs from George Washington University’s Elliott School of International Affairs where she was elected to Phi Beta Kappa and an M.B.A. from The Wharton School of The University of Pennsylvania.
K. Peter Hirth, PhD
Dr. Hirth has served as a member of Iconic Therapeutics’ Board of Directors since May 2015. He has more than 30 years of drug discovery and development expertise. He currently serves as a Board member of Spinomix, KineMed, Kolltan Pharmaceuticals, Afferent Pharmaceuticals and Alios Biopharma. Most recently, Dr. Hirth served as co-founder and CEO of Plexxikon, Inc., where he built a novel, structure-guided drug discovery platform, which has brought several new chemical entities (NCEs) into the clinic such as Zelboraf®, which was approved by the FDA for metastatic melanoma together with a companion diagnostic. Before that, Dr. Hirth was with Sugen Inc., where he was instrumental in building the company from its inception, advancing several kinase inhibitors through clinical trials in oncology. Prior to Sugen, Dr. Hirth was a Vice President of Research at Boehringer Mannheim where he successfully led the company’s erythropoietin program to approval. Earlier in his career, Dr. Hirth was a research scientist with the Max Planck Institute, following the completion of his post-doctoral work at the University of California, San Diego. He received his Ph.D. in molecular genetics from Heidelberg University, Germany.
Bruce Robertson, PhD
Dr. Robertson has served as a member of Iconic Therapeutics’ Board of Directors since April 2014. He is a Managing Director at H.I.G. BioVentures, where he focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices and diagnostics. He currently serves on the Boards of Apollo Endosurgery, CardioFocus, Cerephex, Clarus Therapeutics and Intersection Medical. Prior to joining H.I.G., Dr. Robertson served as Managing Director at Toucan Capital, an early-stage venture capital fund focusing on life science investments, and previously was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the U.S., India, and China. Prior to his venture capital career, Dr. Robertson was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN’s partnering and M&A strategies. He started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices. Dr. Robertson is on the Boards of the Mid-Atlantic Venture Association, Adventist Healthcare, the University of Delaware Research Foundation, and the BioLife Fund of Virginia’s Center for Innovative Technology. He holds a B.S.E. in chemical engineering and a B.A. in mathematics from the University of Pennsylvania, a Ph.D. in chemical/biomedical engineering from the University of Delaware, and an M.B.A. with High Distinction from Harvard Business School.
Independent expert ophthalmology development
Dirk has more than 31 years of extensive experience in Pharmaceutical Research and Development and successfully led numerous projects and teams during all phases of the drug development process.
Dirk joined Novartis in 1989 as a postdoctoral fellow in the Neuroscience Preclinical Research Department. He subsequently held various positions of increasing responsibilities within preclinical research, clinical research and project management working on acute and chronic neurodegenerative diseases such as Stroke, Head Trauma, Parkinson’s Disease, Alzheimer’s Disease and ALS.
In 2005 Dirk joined the Ophthalmology Business Unit at Novartis as Senior Global Project Leader for Visudyne and Lucentis. In October 2011 Dirk was appointed Global Development Unit Head for the Novartis Ophthalmology Development Unit, which since February 2016 includes the development unit of the former Alcon Pharma franchise.
End of March 2021 Dirk retired from Novartis and since then is functioning as an independent consultant and board member for companies within the field of Ophthalmology.
Dirk has a degree in Pharmacy from the University of Münster, Germany and a Ph.D. in Pharmacology from the University of Marburg, Germany.